Compare NMTC & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMTC | NOTV |
|---|---|---|
| Founded | 2009 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5M | 29.9M |
| IPO Year | N/A | 1997 |
| Metric | NMTC | NOTV |
|---|---|---|
| Price | $0.57 | $0.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.23 | ★ $3.00 |
| AVG Volume (30 Days) | 159.1K | ★ 1.6M |
| Earning Date | 12-15-2025 | 12-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,629,051.00 | ★ $513,024,000.00 |
| Revenue This Year | $162.84 | $6.26 |
| Revenue Next Year | $26.51 | $45.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 69.00 | 4.54 |
| 52 Week Low | $0.40 | $0.66 |
| 52 Week High | $1.39 | $6.48 |
| Indicator | NMTC | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 32.46 | 36.94 |
| Support Level | $0.66 | $0.79 |
| Resistance Level | $0.75 | $0.86 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 4.63 | 14.94 |
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.